JP7127988B2 - 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法 - Google Patents

新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法 Download PDF

Info

Publication number
JP7127988B2
JP7127988B2 JP2017540788A JP2017540788A JP7127988B2 JP 7127988 B2 JP7127988 B2 JP 7127988B2 JP 2017540788 A JP2017540788 A JP 2017540788A JP 2017540788 A JP2017540788 A JP 2017540788A JP 7127988 B2 JP7127988 B2 JP 7127988B2
Authority
JP
Japan
Prior art keywords
cxcr4
antagonists
ccr2
ccr3
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505187A5 (https=
JP2018505187A (ja
JPWO2016120369A5 (https=
Inventor
ベルガー，パトリック
デュパン，イザベル
ジロデ，ピエール－オリビエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Bordeaux
Original Assignee
Centre Hospitalier Universitaire de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Bordeaux filed Critical Centre Hospitalier Universitaire de Bordeaux
Publication of JP2018505187A publication Critical patent/JP2018505187A/ja
Publication of JP2018505187A5 publication Critical patent/JP2018505187A5/ja
Publication of JPWO2016120369A5 publication Critical patent/JPWO2016120369A5/ja
Application granted granted Critical
Publication of JP7127988B2 publication Critical patent/JP7127988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017540788A 2015-01-28 2016-01-28 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法 Active JP7127988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152886.6A EP3050574B1 (en) 2015-01-28 2015-01-28 Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
EP15152886.6 2015-01-28
PCT/EP2016/051771 WO2016120369A1 (en) 2015-01-28 2016-01-28 New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease

Publications (4)

Publication Number Publication Date
JP2018505187A JP2018505187A (ja) 2018-02-22
JP2018505187A5 JP2018505187A5 (https=) 2022-05-30
JPWO2016120369A5 JPWO2016120369A5 (https=) 2022-05-30
JP7127988B2 true JP7127988B2 (ja) 2022-08-30

Family

ID=52434596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540788A Active JP7127988B2 (ja) 2015-01-28 2016-01-28 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法

Country Status (12)

Country Link
US (1) US10813911B2 (https=)
EP (2) EP3050574B1 (https=)
JP (1) JP7127988B2 (https=)
CN (1) CN107405405B (https=)
AU (1) AU2016212067B2 (https=)
BR (1) BR112017016347A2 (https=)
CA (1) CA2972319C (https=)
DK (1) DK3050574T3 (https=)
EA (1) EA201791689A1 (https=)
ES (1) ES2764840T3 (https=)
IL (1) IL253688B2 (https=)
WO (1) WO2016120369A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127810A1 (en) * 2016-01-22 2017-07-27 Indiana University Research & Technology Corporation Methods for repairing lung tissue
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease
CN119925562B (zh) * 2023-11-03 2025-11-28 中国科学院上海药物研究所 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用
KR20250133491A (ko) * 2024-02-28 2025-09-08 재단법인 오송첨단의료산업진흥재단 인간 ccl7에 결합하는 신규한 항체 및 이의 용도
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
CA2171761C (en) 1993-09-14 2011-11-15 Timothy John Williams Eotaxin: eosinophil chemotactic cytokine
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
DE69709647T2 (de) 1996-05-20 2002-11-07 Dupont Pharmaceuticals Research Laboratories, Inc. Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
EP1003743A4 (en) 1997-01-21 2001-04-11 Merck & Co Inc 3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
KR100447553B1 (ko) 1997-02-26 2004-09-08 화이자 인코포레이티드 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도
US6207155B1 (en) 1997-05-07 2001-03-27 Schering Corporation Method of eosinophil depletion with antibody to CCR 3 receptor
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP4312957B2 (ja) 1998-01-15 2009-08-12 キングス・カレツジ・ロンドン Ｃｃｒ５あるいはｃｘｃｒ４を開裂するリボザイム核酸
AU760208B2 (en) 1998-02-27 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The G protein-coupled receptor antagonists
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
EP1050583A4 (en) 1998-11-24 2005-02-02 Hisamitsu Pharmaceutical Co INHIBITORS OF HIV INFECTIONS
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
CA2399080C (en) 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
US20050124569A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
EP1461300B1 (en) 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
AR041786A1 (es) 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
PL375263A1 (en) 2002-07-02 2005-11-28 F.Hoffmann-La Roche Ag 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
AU2004215679A1 (en) 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
US20050069955A1 (en) 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
AR046594A1 (es) 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
JP2007523159A (ja) 2004-02-20 2007-08-16 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド Ｒｎａ干渉分子の標的送達
AR049386A1 (es) 2004-05-26 2006-07-26 Janssen Pharmaceutica Nv Mercaptoimidazoles como antagonistas del receptor ccr2
US20060069123A1 (en) 2004-09-28 2006-03-30 Mingde Xia Substituted dipiperidine CCR2 antagonists
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
GB0517966D0 (en) 2005-09-02 2005-10-12 Novartis Ag Organic compounds
HUP0500877A2 (en) 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
WO2007147026A2 (en) 2006-06-15 2007-12-21 Centocor, Inc. Ccr2 antagonists for chronic organ transplantation rejection
WO2008049874A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
CL2008001467A1 (es) 2007-05-30 2008-12-05 Lilly Co Eli Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
PL2175859T3 (pl) 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
HUP0800478A2 (en) 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
WO2010069979A1 (en) 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
HUE025547T2 (en) 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
US8471004B2 (en) 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
US8445674B2 (en) 2009-10-21 2013-05-21 Hoffmann-La Roche Inc Heterocyclyl compounds
JP5356323B2 (ja) * 2010-07-01 2013-12-04 富士化学工業株式会社 新規な非晶質ボセンタン及びその製造方法
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
US8921559B2 (en) 2010-12-01 2014-12-30 Janssen Pharmaceutica Nv 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
EP2685824A4 (en) 2011-03-17 2014-09-10 Merck Sharp & Dohme INDUSTRIAL DERIVATIVES USED AS CCR2 ANTAGONISTS
US20140178367A1 (en) 2011-04-07 2014-06-26 The Brigham And Women's Hospital, Inc. Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2)
HK1197159A1 (en) * 2011-05-25 2015-01-09 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
WO2013000922A1 (en) 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Ccr2 antagonist peptides
WO2013052844A1 (en) * 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
AU2011379300A1 (en) * 2011-10-18 2014-06-05 Biocon Limited Acid addition salts of Bosentan
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
US20160015786A1 (en) * 2013-03-01 2016-01-21 Mater Medical Research Institute Limited Mobilizing agents and uses therefor
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
１０３０３８４－９８－５・ＣＴＣＥ ９９０８・ＣＴＣＥ ９９０８【詳細情報】， 試薬－富士フイルム和光純薬， 検索日：２０２２年２月１日、インターネット＜ＵＲＬ： ｈｔｔｐｓ：／／ｌａｂｃｈｅｍ－ｗａｋｏ．ｆｕｊｉｆｉｌｍ．ｃｏｍ／ｊｐ／ｐｒｏｄｕｃｔ／ｄｅｔａｉｌ／Ｗ０１ＴＯＣ５１３０．ｈｔｍｌ＞
ＡＰＥｘＢＩＯ － ＢＫＴ１４０， ＣＸＣＲ４ ａｎｔａｇｏｎｉｓｔ， ＣＡＳ＃ ６６４３３４－３６－５， 検索日：２０２２年２月１日、インターネット＜ ＵＲＬ： ｈｔｔｐｓ：／／ｗｗｗ．ａｐｅｘｂｔ．ｃｏｍ／ｂｋｔ１４０．ｈｔｍｌ＞
Ｂｕｒｉｘａｆｏｒ ｈｙｄｒｏｂｒｏｍｉｄｅ （ＴＧ－００５４ ｈｙｄｒｏｂｒｏｍｉｄｅ）， ＣＸＣＲ４ Ａｎｔａｇｏｎｉｓｔ， ＭｅｄＣｈｅｍＥｘｐｒｅｓｓ， 検索日：２０２２年２月１日、インターネット＜ＵＲＬ： ｈｔｔｐｓ：／／ｗｗｗ．ｍｅｄｃｈｅｍｅｘｐｒｅｓｓ．ｃｏｍ／Ｂｕｒｉｘａｆｏｒ＿ｈｙｄｒｏｂｒｏｍｉｄｅ．ｈｔｍｌ？ｌｏｃａｌｅ＝ｊａ－ＪＰ＞
ＫＡＤＤＡＨ， Ｓ． ｅｔ ａｌ．，Ｔｈｅ Ｅｇｙｐｔｉａｎ Ｓｏｃｉｅｔｙ ｏｆ Ｃｈｅｓｔ Ｄｉｓｅａｓｅｓ ａｎｄ Ｔｕｂｅｒｃｕｌｏｓｉｓ，２０１４年，Ｖｏｌ．６３， Ｎｏ．４，ｐｐ．８０５－８１３．
Ｓｏｎｇ ｅｔ ａｌ．，Ｅｘｐｅｒｉｍｅｎｔａｌ ａｎｄ Ｍｏｌｅｃｕｌａｒ Ｍｅｄｉｃｉｎｅ，２０１０年，Ｖｏｌ．４２，Ｎｏ．６，ｐｐ．４６５－４７６．
Ｗａｎｇ ｅｔ ａｌ．，Ｂｉｏｌｏｇｉｃａｌ ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ，２０１４年，Ｖｏｌ．３７， Ｎｏ．１０，ｐｐ．１５９１－１５９８．
一ノ瀬正和，日本内科学会雑誌，２０１３年，Ｖｏｌ．１０２， Ｎｏ．７，ｐｐ．１８２２－１８２８

Also Published As

Publication number Publication date
IL253688A (en) 2017-09-28
BR112017016347A2 (pt) 2018-03-27
ES2764840T3 (es) 2020-06-04
WO2016120369A1 (en) 2016-08-04
EP3613435A1 (en) 2020-02-26
EP3050574A1 (en) 2016-08-03
US20180271831A1 (en) 2018-09-27
CA2972319A1 (en) 2016-08-04
CN107405405A (zh) 2017-11-28
DK3050574T3 (da) 2020-01-20
AU2016212067B2 (en) 2020-10-08
EP3050574B1 (en) 2019-10-09
AU2016212067A1 (en) 2017-09-14
CA2972319C (en) 2023-08-01
IL253688B2 (en) 2023-05-01
EA201791689A1 (ru) 2017-11-30
US10813911B2 (en) 2020-10-27
IL253688B1 (en) 2023-01-01
JP2018505187A (ja) 2018-02-22
CN107405405B (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
JP7127988B2 (ja) 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
US8178091B2 (en) Compositions and methods for the treatment of respiratory disorders
US20210322515A1 (en) Methods for treating fibrotic cancers
US9198900B2 (en) Treatment of peritoneal injury using JAK inhibitors
US10450371B2 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
CN115803023A (zh) 发用奈珠西替尼治疗感染冠状病毒的患者的方法
US20140037548A1 (en) Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
US20090105281A1 (en) Methods of treating inflammation
JP2025519561A (ja) Ｇｐｃｒ阻害剤及びその使用
US20110319405A1 (en) Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
US9511086B2 (en) Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis
Huang et al. GPR56/ADGRG1 induces biased Rho-ROCK-MLC and JAK-STAT3 signaling to promote amoeboid-like morphology and IL-6 upregulation in melanoma cells
US20090239884A1 (en) Methods of Treating Inflammation
CN101005855A (zh) 治疗由ccr2介导的疾病或紊乱的方法
EA040016B1 (ru) Применение композиции, содержащей антагонист или ингибитор рецептора хемокинов cxcr4 для изготовления лекарственного средства для предупреждения и/или лечения copd и aecopd, способ подавления миграции фиброцитов у пациентов с copd или aecopd и набор
WO2022174098A1 (en) Methods for blocking her2 signaling for treating pulmonary fibrosis
EP3256121B1 (en) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
CN113811321A (zh) 新型选择性ackr3调节剂及其用途
WO2024177898A1 (en) Cleavage products of angiopoietin-2 and methods of use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201120

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210125

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210126

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210305

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210309

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211102

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220216

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220512

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220601

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220620

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220721

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220818

R150 Certificate of patent or registration of utility model

Ref document number: 7127988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250